Newsfeeds Archive - Spark Newswire

4 minute read

Belite Bio Presents Additional Analysis From Phase 2 Study Of Tinlarebant In Stargardt Disease At The ARVO Annual Meeting

May 6, 8:21 AM

Additional analysis of visual acuity loss, genotypic profiles, and retinal imaging data from a 24-month Phase 2 trial of Tinlarebant in adolescent Stargardt disease patients provides further support for the potential of

BLTE

2 minute read

Analyst Ratings

Expert Ratings for Belite Bio

By Benzinga Insights

December 14, 1:00 PM

Over the past 3 months, 4 analysts have published their opinion on Belite Bio (NASDAQ:BLTE) stock. These analysts…

BLTE

1 minute read

FDA
News

Belite Bio Received Approval To Initiate Tinlarebant Phase 3 Clinical Trial For GA in Switzerland

By Charles Gross

December 10, 1:45 PM

Belite Bio, Inc (NASDAQ:BLTE), a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting retinal degenerative eye diseases which have significant unmet medical needs,

BLTE

12 minute read

Earnings

Earnings Scheduled For November 14, 2023

By Benzinga Insights

November 14, 9:23 AM

Companies Reporting Before The Bell • CureVac (NASDAQ:CVAC) is likely to report quarterly loss at $0.24 per share on revenue of $18.00 million.

ACXP

3 minute read

Belite Bio Announces NMPA Submission For Tinlarebant Phase 3 GA Clinical Trial In China

By Benzinga Newsdesk

October 17, 4:24 PM

Tinlarebant (a/k/a LBS-008) is Belite Bio’s orally administered tablet intended to slow disease progression in patients affected with Stargardt Disease (STGD1) and Geographic Atrophy (GA) in advanced Dry Age-related Macular Degeneration (Dry AMD)

BLTE

4 minute read

Why 22nd Century Group Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Monday’s Mid-Day Session

By Lisa Levin

August 14, 12:49 PM

Gainers Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) shares jumped 283.7% to $1.3007 after Harmony Biosciences entered into definitive agreement to acquire the company for total potential consideration of up to $200 million in cash.

$APE

2 minute read

Analyst Ratings

Expert Ratings for Belite Bio

By Benzinga Insights

August 10, 3:00 PM

Analysts have provided the following ratings for Belite Bio (NASDAQ:BLTE) within the last quarter: Bullish Somewhat Bullish Indifferent…

BLTE

22 minute read

Earnings

Earnings Scheduled For August 9, 2023

By Benzinga Insights

August 9, 4:54 AM

Companies Reporting Before The Bell • Sony Group (NYSE:SONY) is estimated to report quarterly earnings at $0.96 per share on revenue of $18.11 billion.

AADI

3 minute read

Belite Bio Receives Approval To Initiate Tinlarebant Phase 3 Clinical Trial For Ga In Australia

By Benzinga Newsdesk

August 4, 8:08 AM

Tinlarebant (a/k/a LBS-008) is Belite Bio's orally administered tablet intended to slow disease progression in patientsaffected with Stargardt Disease (STGD1) and Geographic Atrophy (GA) in advanced Dry Age-related

BLTE